论文部分内容阅读
目的探讨两种药物联合治疗重度妊娠期肝内胆汁淤积症(ICP)患者的临床疗效及对母婴结局的影响。方法选择2015年7月-2016年7月在该院接受治疗的105例重度ICP患者为研究对象,采用双盲法将其分为观察组(53例)和对照组(52例)。对照组患者单纯予以思美泰治疗,观察组患者在此基础上予以熊去氧胆酸治疗,比较两组患者的治疗效果及母婴结局。结果经过治疗观察组患者的瘙痒评分、各项生化指标及母婴结局均明显优于对照组,差异有统计学意义(均P<0.05)。结论对ICP患者予以思美泰联合熊去氧胆酸治疗能够有效改善患者的临床症状,改善母婴结局,提高治疗总有效率。
Objective To investigate the clinical effects of two drugs in the treatment of patients with intrahepatic cholestasis of severe pregnancy (ICP) and their effects on maternal and infant outcomes. Methods 105 severe ICP patients treated in our hospital from July 2015 to July 2016 were enrolled in the study. The patients were divided into observation group (53 cases) and control group (52 cases) by double-blind method. Patients in the control group were treated with Smectite alone, and the patients in the observation group were treated with ursodeoxycholic acid on the basis of this treatment. The treatment effect and maternal and infant outcomes of the two groups were compared. Results The scores of pruritus, biochemical and maternal and infant outcomes in the treatment group were significantly better than those in the control group (all P <0.05). Conclusion The combination of Smectite and ursodeoxycholic acid in patients with ICP can effectively improve the clinical symptoms, improve maternal and infant outcomes and improve the total effective rate of treatment.